Overview
Dr. DeVore is a cardiologist and Associate Professor of Medicine in the Department of Medicine, Division of Cardiology, at Duke University School of Medicine. His clinical interests include caring for patients and families with heart failure, including those with left ventricular assist devices and heart transplants. He is involved in and leads multiple large studies of patients with heart failure at both Duke University Medical Center and the Duke Clinical Research Institute. He currently serves as the medical director of the Duke Heart Transplant program.
He attended medical school at the University of Chicago Pritzker School of Medicine and completed internal medicine residency at Brigham and Women’s Hospital. He then pursued cardiology training at Duke University and solidified his interests in clinical research and heart failure. He completed a research fellowship at the Duke Clinical Research Institute and a Masters of Health Sciences in Clinical Research before completing an advanced heart failure fellowship at Duke University.
The overarching goals of his research are to advance the current understanding of heart failure through clinical trials as well as develop an evidence base for implementation strategies that addresses the gap between heart failure trial results and clinical practice. For example, he has served on the Steering Committees for large clinical trials, including PIONEER-HF and SPIRRIT-HFpEF. Dr. DeVore also published the first clinical trial conducted within the American Heart Association’s Get With The Guidelines-Heart Failure program, a registry-based cluster randomized trial of quality improvement interventions. He was also the principal investigator for CONNECT-HF, a large-scale, pragmatic, cluster-randomized trial at 161 sites in the US evaluating heart failure quality improvement initiatives. Outside of his work on heart failure, Dr. DeVore is married with 4 children and spends his time corralling them all and coaching youth baseball.
Current Appointments & Affiliations
Recent Publications
Remote digital intervention targeting heart failure medical therapy: a randomized controlled trial.
Journal Article Lancet Reg Health Am · June 2026 BACKGROUND: Heart failure (HF) causes substantial morbidity and mortality, in part because evidence-based pharmacotherapies remain underused. Remote, asynchronous digital platforms may accelerate the initiation and titration of pharmacotherapies outside of ... Full text Link to item CiteImpact of HeartMate 3 left ventricular assist device infection on outcomes following heart transplant.
Journal Article J Heart Lung Transplant · April 2026 BACKGROUND: Infectious complications are common in patients implanted with HeartMate 3 (HM3) left ventricular assist devices (LVAD). Despite these issues, some patients with LVAD-specific infection are ultimately considered for heart transplant (HT). The i ... Full text Link to item CiteOrgan-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience.
Journal Article Am J Transplant · March 26, 2026 Cytomegalovirus (CMV) causes significant morbidity in CMV donor seropositive/recipient seronegative (D+R-) solid organ transplant recipients, but organ-specific differences in CMV epidemiology and the utility of laboratory surveillance after prophylaxis (S ... Full text Link to item CiteRecent Grants
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO ASSESS EFFICACY AND SAFETY OF OMECAMTIV MECARBIL IN PATIENTS WITH SYMPTOMATIC HEART FAILURE WITH SEVERELY REDUCED EJECTION FRACTION
Clinical TrialPrincipal Investigator · Awarded by Cytokinetics, Inc. · 2025 - 20291/2 Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Extension Trial
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2028Merck - CHA - Guidelines Implementation Study - Industry
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2025 - 2027View All Grants